aTyr Pharma Inc (NASDAQ:LIFE) saw a significant increase in short interest in August. As of August 31st, there was short interest totalling 140,500 shares, an increase of 16.9% from the July 31st total of 120,200 shares. Based on an average daily volume of 111,100 shares, the days-to-cover ratio is presently 1.3 days. Currently, 4.5% of the shares of the company are sold short.
Several research firms have recently issued reports on LIFE. Citigroup set a $4.00 price target on aTyr Pharma and gave the stock a “hold” rating in a research note on Friday, August 30th. ValuEngine raised aTyr Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, July 2nd. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $12.07.
Hedge funds have recently made changes to their positions in the stock. Wedbush Securities Inc. boosted its stake in aTyr Pharma by 158.7% during the second quarter. Wedbush Securities Inc. now owns 67,270 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 41,271 shares in the last quarter. Vanguard Group Inc. boosted its stake in aTyr Pharma by 1.9% during the second quarter. Vanguard Group Inc. now owns 1,779,024 shares of the biotechnology company’s stock valued at $652,000 after buying an additional 33,702 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in aTyr Pharma by 19.8% during the second quarter. Renaissance Technologies LLC now owns 1,845,873 shares of the biotechnology company’s stock valued at $676,000 after buying an additional 305,314 shares in the last quarter.
aTyr Pharma (NASDAQ:LIFE) last released its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($1.80) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.74) by $0.94. The business had revenue of $0.09 million during the quarter.
aTyr Pharma Company Profile
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD.
Recommended Story: Systematic Risk and Investors
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.